XGN - Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Management will participate in one-on-one investor meetings on Tuesday, February 11??, 2025, at the Cliff Lodge located in Snowbird, UT.
TD Cowen’s 45?? Annual Health Care Conference
John Aballi, President and CEO and Jeff Black, CFO, will participate in a fireside chat at 1:10 p.m. EST on Wednesday, March 5??, 2025, at the Marriott Copley Place in Boston, MA. Management will also participate in one-on-one investor meetings.
5?? Annual KeyBanc Capital Markets Healthcare Forum
Management will participate virtually in a fireside chat at a time to be determined and one-on-one investor meetings on Tuesday, March 18??, 2025.
Please check the Events section of the Investors page on Exagen.com for more information and links to the fireside chats.
About Exagen
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE ® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).
Exagen Inc.
Ryan Douglas
IR@exagen.com
760.560.1525